SPOTLIGHT: Cancer drug flunks Phase III


BioNumerik Pharmaceuticals and ASKA Pharmaceutical said that a late-stage trial of Tavocept failed to produce a statistically significant response in patients with advanced non-small cell lung cancer. Researchers say that the small number of patients in the trial was probably responsible for the failure, though it highlighted the fact that researchers observed a 50 percent decrease in severe sporadic or cumulative neuropathy. "A surprising and medically important observation from the trial was an observed increase in the median survival time for patients receiving Tavocept as compared to those receiving placebo." Release

Suggested Articles

Almirall and Iktos will use the latter's AI technology to design new compounds that tick multiple drug criteria boxes.

Pfizer’s 2017 spinout company SpringWorks has lost president and founder Lara Sullivan, M.D., who has moved over to Pyxis Oncology as its new chief.

In this week's EuroBiotech Report, Sanofi inks $2.5B Synthorx takeover and posts sutimlimab data, Roche shares bispecific results and more.